ImpediMed Limited

ImpediMed Limited

ImpediMed Limited was founded in 1987 and is headquartered in Carlsbad, California, with operations in the United States, Europe, and Australia. The company is listed on the Australian Stock Exchange and focuses on noninvasive bioimpedance spectroscopy (BIS) devices for clinical assessment of fluid status and tissue composition. Its primary initial application was secondary lymphedema, particularly breast cancer-related lymphedema (BCRL). The company's SOZO Digital Health Platform, cleared by the FDA, delivers whole-body composition insights by measuring 256 frequencies in a single scan. The platform offers three key analyses: L-Dex for early lymphedema detection, BodyComp for tracking fluid volumes and tissue composition, and HF-Dex for monitoring fluid changes in heart failure patients. Clinically, ImpediMed addresses cancer survivorship (where up to 58% of patients face lymphedema risk), wellness and longevity, medical weight management (GLP-1 therapy can reduce muscle mass up to 20%), and heart health management affecting ~64 million people globally. The platform is cloud-connected, allowing longitudinal patient monitoring across care settings. As of 2026, the company is led by CEO Erik Anderson, appointed in a recent leadership change; Anderson also serves on the board following his earlier appointment as a medical technology commercialisation expert. The team size and additional offices beyond Carlsbad are not publicly detailed. ImpediMed is publicly traded on the ASX and does not disclose AUM or investment deployment figures, as the firm is an operating medical device company rather than an asset manager. ImpediMed's structural distinction lies in its focus on a single diagnostic technology (BIS) applied across multiple chronic conditions — lymphedema, heart failure, and GLP-1-related muscle loss — with each application supported by peer-reviewed clinical evidence. The company is not a family office or investment vehicle but a publicly listed medtech firm whose proprietary platform generates real-world outcomes data that in turn informs its product roadmap and regulatory strategy.